Citation Impact
Citing Papers
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
2009 Standout
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
2008
Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer
2008
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
2010
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
2009
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
2011 Standout
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
2014 StandoutNobel
TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth
2007
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study
2014
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
2011 Standout
Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations
2006
Gastric cancer
2016 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
2008
Engineering precision nanoparticles for drug delivery
2020 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
2016 Standout
Pancreatic cancer
2004 Standout
Breast cancer
2016 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
UNUSUAL TYPES OF THYROID NEOPLASMS
1996
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Ovarian cancer
2014 Standout
Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: A randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group
2006
Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting
2000
Estrogen receptor α is a major mediator of 17β-estradiol’s atheroprotective effects on lesion size in Apoe–/– mice
2001 StandoutNobel
Cancer, Inflammation, and Therapy: Effects on Cytochrome P450–Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents
2014
Advanced pancreatic carcinoma: current treatment and future challenges
2010
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Pancreatic cancer
2016 Standout
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 Standout
Lumpectomy Plus Tamoxifen or Anastrozole With or Without Whole Breast Irradiation in Women With Favorable Early Breast Cancer
2007
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
Osteoporosis: now and the future
2011 Standout
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
2002
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Pancreatic Adenocarcinoma
2014 Standout
Estradiol inhibition of arterial neointimal hyperplasia after balloon injury
1994
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Nasopharyngeal carcinoma
2015 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
2010
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Cisplatin-Based Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Implications of Eastern Cooperative Oncology Group 5592, a Randomized Trial
2002
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Exemestane: an alternative treatment option in early breast cancer
2008
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer
2004
Role of gemcitabine in cancer therapy
2005
Pancreatic Cancer
2010 Standout
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
2008
Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis
2004
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation
2017 StandoutNobel
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Salvage gemcitabine–vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy
2012
Advances in Malignant Mesothelioma
2005 Standout
Pancreatic cancer
2011 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2016
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
2013
Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis Inhibitor
2008
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Decrease in topoisomerase I is responsible for activation-induced cytidine deaminase (AID)-dependent somatic hypermutation
2011 StandoutNobel
Breast Cancer Treatment
2019 Standout
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
2007
Randomized phase II /III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS ‐PC Study
2015
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial
2007
Structural and Biochemical Studies of a Fluoroacetyl-CoA-Specific Thioesterase Reveal a Molecular Basis for Fluorine Selectivity
2010 StandoutNobel
Ratiometric delivery of cisplatin and doxorubicin using tumour-targeting carbon-nanotubes entrapping platinum(iv ) prodrugs
2014
Comprehensive Geriatric Assessment for Older Patients With Cancer
2007
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
2009
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2016
Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.
2002
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
2006
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
2015
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
2010
Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade
2007
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Thyroid carcinoma
2003 Standout
Programmed co-delivery of platinum nanodrugs and gemcitabine by a clustered nanocarrier for precision chemotherapy for NSCLC tumors
2019
Works of B. Massidda being referenced
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study
2006
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)
2005
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group
2009
Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial
2005
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study
2015
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
2013
Randomized, Controlled, Multicenter Phase III Trial of Standard-Dose Fluorouracil-Epirubicin- Cyclophosphamide (FEC), Compared with Time-Intensive FEC (FEC-G) and Mitoxantrone-Methotrexate-Mitomycin C (MMM-G) in Metastatic Breast Carcinoma
2003
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial
2006
Prevention of Delayed Emesis by a Single Intravenous Bolus Dose of 5-HT3-Receptor- Antagonist in Moderately Emetogenic Chemotherapy
1996
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
2000
Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole Trial
2005
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study
2010
[Estrogen therapy of advanced breast cancer].
1977
A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas— GOIM/GISCAD/GOIRC) study
2009
[Anaplastic carcinoma of the thyroid. Our experience].
1992
Cisplatin, Gemcitabine, and Paclitaxel in Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: A Phase I-II Study
1999